MoonLake Immunotherapeutics第一季度每股收益低于预期，股价下跌，但维持“买入”评级。 MoonLake Immunotherapeutics Q1 EPS missed estimates and stock fell, but keep "buy" ratings.

MoonLake Immunotherapeutics （MLTX）公布第一季度每股收益为0.39美元，预期为0.28美元，股价下跌1.80美元至44.25美元。 MoonLake Immunotherapeutics (MLTX) reported Q1 EPS miss of ($0.39) vs. ($0.28) est., and stock fell $1.80 to $44.25. 尽管如此,尼德姆,HC韦恩赖特和奥本海默仍然保持"买入"评级,目标价格在62美元至104美元之间. Despite this, Needham, HC Wainwright, and Oppenheimer kept "buy" ratings, with price targets ranging from $62-$104. MLTX是临床阶段生物药剂,重点是Sonelokimab等炎症治疗。 MLTX, a clinical-stage biopharma, focuses on inflammation disease therapies like Sonelokimab.